Wellington Shields Capital Management’s Royalty Pharma RPRX Stock Holding History

Wellington Shields Capital Management’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-48,007	Closed	-$1.9M	–	332
2022 Q4	$1.9M	Sell	48,007 -49,166	-51%	-$2.05M	0.23%	59
2022 Q3	$3.9M	Hold	97,173	–	–	0.93%	23
2022 Q2	$4.08M	Buy	97,173 +2,500	+3%	+$102K	0.51%	22
2022 Q1	$3.69M	Hold	94,673	–	–	0.4%	33
2021 Q4	$3.77M	Buy	94,673 +3,032	+3%	+$118K	0.48%	47
2021 Q3	$3.31M	Buy	91,641 +1	+0%	+$39	0.45%	40
2021 Q2	$3.76M	Hold	91,640	–	–	0.45%	44
2021 Q1	$4M	Sell	91,640 -2,000	-2%	-$94.8K	0.38%	52
2020 Q4	$4.69M	Buy	+93,640	New	+$3.97M	0.63%	33

Other funds holding RPRX

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Shields Capital Management's RPRX Position: Q1 2023 in Review

Wellington Shields Capital Management sold out of Royalty Pharma (RPRX) in Q1 2023, closing a stake of 48,007 shares — an estimated $1.9M sold.

Wellington Shields Capital Management first reported a position in RPRX in Q4 2020 and held it in 9 quarters. The position peaked at $4.69M in Q4 2020. 335 funds tracked by Wall St. Rank hold RPRX as of Q1 2023.

Wellington Shields Capital Management reported no remaining Royalty Pharma position as of Q1 2023 after selling out during the quarter.
Wellington Shields Capital Management sold 48,007 Royalty Pharma shares in Q1 2023, an estimated $1.9M.
Wellington Shields Capital Management first reported a position in Royalty Pharma in Q4 2020 and held it in 9 quarters.
Wellington Shields Capital Management's Royalty Pharma position peaked at $4.69M in Q4 2020.
335 funds tracked by Wall St. Rank held Royalty Pharma as of Q1 2023.

Based on Wellington Shields Capital Management's 13F filing for Q1 2023, filed 11 May 2023.